JPEG iPSC differentiated Myotubes (1).jp
JPEG UTRNdelIMTR iPSC_oct4_a-tub
JPEG UTRNdelIMTR iPSC_oct4_a-tub

press to zoom
F3 DAPI-ASG inset
F3 DAPI-ASG inset

press to zoom
F3 DAPI-MF20 inset
F3 DAPI-MF20 inset

press to zoom
JPEG UTRNdelIMTR iPSC_oct4_a-tub
JPEG UTRNdelIMTR iPSC_oct4_a-tub

press to zoom
1/5

MYOARETE

INNOVATIVE THERAPIES FOR TREATING ALL DMD PATIENTS

DISEASES
 
DISEASES
 

Duchenne Muscular Dystrophy (DMD) is a devastating genetic disease. Currently, there is no cure for DMD.  We at MyoArete are committed toward developing innovative therapies for treating all DMD patients. 

The MyoArete pipeline consists of utrophin upregulation-based products for treatments for DMD. These treatments are predicted to benefit all DMD patients, regardless of mutation.

 

PIPELINE
 

MyoArete is an innovative biopharmaceutical startup focused on developing cures for DMD. We use new platform technologies developed at the founder's laboratory at the University of Pennsylvania and exclusively licensed to MyoArete.

 

ABOUT US
 

CONTACT US

Tejvir S. Khurana, MD, PhD. ,

Department of Physiology & Pennsylvania Muscle Institute,

Perelman School of Medicine, University of Pennsylvania,

750 Clinical Research Building (CRB),

415 Curie Boulevard,

Philadelphia, PA 19104-6085

Thanks for submitting!

Neal Lemon, PhD, MBA,

Associate Director,

Penn Center for Innovation (PCI) Licensing Group,  

University of Pennsylvania
3600 Civic Center Boulevard, 9th Floor
Philadelphia, PA 19104

Thanks for submitting!